Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
US Food and Drug Administration. December 13, 2022: Cardiovascular and Renal Drugs Advisory Committee Meeting Announcement. Available from:https://www.fda.gov/advisory-committees/advisory-committee-calendar/december-13-2022-cardiovascular-and-renal-drugs-advisory-committee-meeting-announcement-12132022. Accessed January 4, 2023.
- Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure.N Engl J Med. 2021; 384: 105-116https://doi.org/10.1056/NEJMoa2025797
- Identifying treatments for stage C2 heart failure.JAMA Cardiol. 2022; 7: 34-35https://doi.org/10.1001/jamacardio.2021.4024
- Improving the use of FDA advisory committees.N Engl J Med. 2022; 387: 675-677https://doi.org/10.1056/NEJMp2206492